The Rosen Law Firm has announced a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that uniQure and its executives misrepresented or failed to disclose critical information regarding the FDA approval status of its gene therapy study and potential delays in its BLA timeline. Stockholders with significant losses are urged to contact the firm by April 13, 2026, to learn about their rights to potentially serve as lead plaintiff.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against uniQure N.V. (NASDAQ: QURE) on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that uniQure and its executives misrepresented or failed to disclose critical information regarding the FDA approval status of its gene therapy study and potential delays in its BLA timeline. Stockholders with significant losses are urged to contact the firm by April 13, 2026, to learn about their rights to potentially serve as lead plaintiff.